Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (IFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17P)

Category Primary study
JournalHaematologica
Year 2017
This article has no abstract
Epistemonikos ID: d93663668e1c1acea5eee381f998d5d6d7bd5019
First added on: Feb 08, 2025